- All sections
- A - Human necessities
- A61K - Preparations for medical, dental or toiletry purposes
- A61K 39/116 - Polyvalent bacterial antigens
Patent holdings for IPC class A61K 39/116
Total number of patents in this class: 280
10-year publication summary
|
4
|
26
|
11
|
23
|
17
|
16
|
11
|
25
|
13
|
11
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Glaxosmithkline Biologicals S.A. | 1596 |
36 |
| Pfizer Inc. | 3374 |
7 |
| Novartis AG | 10340 |
6 |
| Cansino Biologics Inc. | 81 |
6 |
| Merck Sharp & Dohme LLC | 3736 |
6 |
| Longhorn Vaccines and Diagnostics, LLC | 92 |
5 |
| Idorsia Pharmaceuticals Ltd. | 332 |
5 |
| SK Bioscience Co., Ltd. | 126 |
5 |
| Wyeth Holdings LLC | 51 |
4 |
| Sanofi Pasteur Inc. | 354 |
4 |
| University of Tennessee Research Foundation | 754 |
4 |
| Previwo AS | 22 |
4 |
| The Regents of the University of Michigan | 4928 |
3 |
| Baxalta GmbH | 103 |
3 |
| Baxalta Incorporated | 300 |
3 |
| Children's Medical Center Corporation | 1939 |
3 |
| Keio University | 1123 |
3 |
| Ohio State Innovation Foundation | 2330 |
3 |
| Sanaria Inc. | 39 |
3 |
| Serum Institute of India Private Limited | 106 |
3 |
| Other owners | 164 |